According to several publications in the official profile of the Cuban institution in X, the agreement is focused on obtaining products that are priorities for medical, sanitary and public health care in both countries.
In this regard, the president of BioCubaFarma, Mayda Mauri, commented that the consolidation of these agreements is the expansion of the internationalization in the research-development activity, which constitutes a priority of attention for this entity in terms of science and innovation in this year 2025.
The Immunoessay Center is a High Technology company that researches, develops, produces and markets products and technologies for in vitro diagnosis, equipment and accessories intended for medical care and the research of hereditary-metabolic, transmissible and chronic non-transmissible diseases.
Another of its lines of work includes technical assistance to laboratories and training of the personnel who employ them in Cuba and in the rest of the world.
SUMA technology stands out among the products of this company and is a fundamental technological support for important national health programs such as the Maternal-Child program for prenatal care and control of mother-fetus transmission of pathologies such as HIV and hepatitis B, as well as in the discovery of congenital malformations.
ef/mem/cdg
